Have Insiders Sold Soleno Therapeutics Shares Recently?

Some Soleno Therapeutics, Inc. (NASDAQ:SLNO) shareholders may be a little concerned to see that the President, Anish Bhatnagar, recently sold a substantial US$966k worth of stock at a price of US$45.78 per share. However, that sale only accounted for 2.9% of their holding, so arguably it doesn't say much about their conviction.

Check out our latest analysis for Soleno Therapeutics

Soleno Therapeutics Insider Transactions Over The Last Year

In fact, the recent sale by President Anish Bhatnagar was not their only sale of Soleno Therapeutics shares this year. Earlier in the year, they fetched US$46.14 per share in a -US$5.8m sale. That means that an insider was selling shares at around the current price of US$44.52. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).

In the last year Soleno Therapeutics insiders didn't buy any company stock. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).

Does Soleno Therapeutics Boast High Insider Ownership?

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data indicates that Soleno Therapeutics insiders own about US$6.9m worth of shares (which is 0.3% of the company). We do generally prefer see higher levels of insider ownership.

So What Do The Soleno Therapeutics Insider Transactions Indicate?

Insiders haven't bought Soleno Therapeutics stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. So we're not rushing to buy, to say the least. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Soleno Therapeutics. For example, Soleno Therapeutics has 3 warning signs (and 1 which is a bit concerning) we think you should know about.

But note: Soleno Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.